about
An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's DiseaseComorbidities of obsessive and compulsive symptoms in Huntington's disease.Irritability in pre-clinical Huntington's diseasePotent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.Therapeutic potential of fluoxetine in neurological disorders.Gene therapy in mouse models of huntington disease.A review of the treatment options for Huntington's disease.A systematic review of the treatment studies in Huntington's disease since 1990.Symptomatic treatment of Huntington diseasePatterns of serotonergic antidepressant usage in prodromal Huntington diseaseSix psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.Results of the citalopram to enhance cognition in Huntington disease trial.Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?Huntington's Disease-Update on Treatments.Novel protective mechanisms of antidepressants against 3-nitropropionic acid induced Huntington's-like symptoms: a comparative study.Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.Worsening Choreoathetosis in Huntington's Disease with Fluoxetine, Lisdexamfetamine, and Melatonin: A Case Report
P2860
Q28477159-222F18BB-CB38-4B52-BDBC-CA91E7FCBC21Q30430896-7E373576-5D21-4170-8DA4-8B6F1BA42867Q33604313-BE58C0D9-A2FC-42C7-B137-45ECAC4BD603Q34221351-36023B75-7B26-4AE1-B9B0-C6A777190F3FQ34778793-9040F7F9-382B-46CD-BEEF-6A166DDA0CC7Q35090208-A8312542-2F74-44E2-9B97-E5EDE08F6F4FQ35753388-A5691189-837E-4B8B-A07D-168068AAAC84Q36719669-11871412-7B7E-408D-8307-D956EE037AD9Q37131233-A0BCB42C-85A4-499D-8D00-BDB087233AB7Q37148863-087C9784-B831-46E0-BE0F-3638369E517EQ37548320-541C9D33-A10B-4147-B033-2B26FF43EF5EQ37607467-7E9A7101-99F9-438E-826B-D954246AA968Q37649788-6DB58F29-DDEB-4BD5-9E6E-699FACE62DCBQ38244078-EB72D768-0742-4CF6-B1D4-623953C6DD5BQ39190617-A28CDCE4-AF79-44A2-A0B7-3365DC345CA5Q43122795-D05002F7-71A5-4247-90AE-FA5908AB795AQ45300518-5B867363-8FBB-4BCA-A7BE-6CBAE16FDF99Q58804263-40F79900-BC08-4A27-920E-2C0D6555C730
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Fluoxetine in the treatment of Huntington's disease.
@ast
Fluoxetine in the treatment of Huntington's disease.
@en
type
label
Fluoxetine in the treatment of Huntington's disease.
@ast
Fluoxetine in the treatment of Huntington's disease.
@en
prefLabel
Fluoxetine in the treatment of Huntington's disease.
@ast
Fluoxetine in the treatment of Huntington's disease.
@en
P2093
P356
P1433
P1476
Fluoxetine in the treatment of Huntington's disease.
@en
P2093
P2888
P304
P356
10.1007/S002130000575
P577
2001-01-01T00:00:00Z
P6179
1005809189